Patients with acute coronary syndromes (ACS) who take ticagrelor are known to be at higher risk for dyspnea than their counterparts who receive clopidogrel. New findings published online January 9, ...

Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. At 12 ...

Please provide your email address to receive an email when new articles are posted on . New data from the HI-TECH study presented at EuroPCR indicate that ticagrelor did not improve endothelial ...

PARIS, France—New randomized data are crossing out a long-held hypothesis many assumed about how the potent antiplatelet agent ticagrelor works. Contrary to expectations, the drug does not appear to ...

Ticagrelor (Brilique, AstraZeneca) is an oral antagonist of the P2Y12 adenosine diphosphate receptor that inhibits platelet aggregation and thrombus formation in atherosclerotic disease. Marketing ...

Adenosine is a nucleoside that occurs naturally in all cells of the body. Chemically it is 6-amino-9-beta-D-ribofuranosyl-9-H-purine. Adenosine is made up of adenine attached to a ribose sugar ...

Please provide your email address to receive an email when new articles are posted on . Ticagrelor was associated with a 29% lower risk for osteoarthritis compared with another antiplatelet agent, ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of extended therapy with ticagrelor 60 mg twice daily plus aspirin (hereafter referred to as ticagrelor), ...